{"filings":[{"id":664276,"accession_number":"0001663577-26-000170","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2026-05-26T18:46:38+00:00","items":["8.1"],"status":"ready","headline":"Bio-Path launches AI-driven digital asset treasury, assigns up to $10M of CEO's $57.9M judgment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Digital Asset Treasury 2.0 using AI to trade and accumulate L1/L2 blockchains; Coinbase account to be opened.","Assignment to company of up to $10M of $57.9M judgment awarded to CEO Vikram Grover vs Net Savings Link; consideration in notes/preferred/common.","Press release (May 14) announced repositioning, added scientific advisors, canceled 1-30 reverse split, engaged advisors for strategic/financial investors.","Judgment from U.S. District Court Northern Illinois, $57.9M plus pre-judgment interest; monetization subject to obtaining custodianship of defendant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101611,"accession_number":"0001663577-26-000064","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["5.03","8.1"],"status":"ready","headline":"Bio-Path Holdings completes domestication to Wyoming, creates Series S Preferred stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Domestication to Wyoming approved March 5, 2026; state of incorporation changed from Delaware.","Created 51 authorized shares of Series S Preferred, each convertible into one common share with 1% diluted voting power.","Appointed Wendy M. Charles and Michael Hickey to Scientific Advisory Board effective Feb 10, 2026.","Each new advisor received 100,000 stock options at $0.06 exercise price, expiring in three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101610,"accession_number":"0001663577-26-000046","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["5.01","5.03","7.1","8.1"],"status":"ready","headline":"Bio-Path issues Series S preferred to CEO entity, giving 51% voting control; cancels reverse split, plans trial restarts","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 51 Series S preferred shares (1% vote each) and 2M warrants to CEO-controlled SGA, granting 51% voting control.","$10K accrued payables used as consideration for the preferred and warrants; no new capital raised.","Filing to domesticate to Wyoming from Delaware; expected approval March 2026.","In talks with creditors to restructure; plans to restart Phase 1/2 trials for AML, solid tumors, and obesity.","Canceled previously approved 1-30 reverse split; created Strategic Advisory Board and reserved 1.5M incentive stock options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117959,"accession_number":"0001663577-25-000317","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Bio-Path warns of going concern doubt, seeks financing; director resigns","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Director Douglas Morris resigned effective Nov 13, 2025; resignation received Nov 4.","Company seeking financing to fund turnaround; plans to update finance team, engage new PCAOB auditors, hire investment bankers to review biotech portfolio for sale/partnership/M&A.","Warns substantial doubt about ability to continue as going concern if capital raise fails; notes risk of delisting from OTC Markets.","No specifics on financing amount or timeline; strategic review of portfolio and M&A pursuits announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117958,"accession_number":"0001663577-25-000303","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bio-Path appoints Vikram Grover as CEO, CFO and director; Morris resigns as interim CEO/CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vikram Grover elected President, CEO, CFO and Board member effective October 22, 2025.","Douglas Morris resigned as Interim CEO and Interim CFO but remains on the Board.","Paul Aubert resigned as director, effective October 22, 2025.","Grover now holds both CEO and CFO roles, consolidating leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134411,"accession_number":"0001104659-25-077665","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Bio-Path Holdings dismisses EY as auditor; no disagreements; seeking replacement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved dismissal of EY as independent auditor on Aug 13, 2025, effective immediately.","EY's reports for FY 2024 and 2023 were unqualified except for a going concern explanatory paragraph.","No disagreements or reportable events with EY during the two most recent fiscal years or interim period.","Company is actively seeking a new independent registered public accounting firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151233,"accession_number":"0001558370-25-008814","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Bio-Path Holdings CEO and entire board resign; operations paused, employees furloughed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO/President/CFO/Chairman Peter H. Nielsen resigned June 20, 2025, from all roles.","Board members Heath Cleaver and Aline Sherwood resigned June 20-21, 2025.","Douglas P. Morris appointed Chairman on June 22, 2025; no changes to his compensation.","Company instituted an operational pause, furloughed most employees, and is seeking financing.","Without financing, company may delay programs, dispose of assets, or liquidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151232,"accession_number":"0001558370-25-006150","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bio-Path announces third pre-clinical milestone for BP1001-A in obesity/Type 2 diabetes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["BP1001-A rescues AKT activity decrease in liver cells, preventing insulin resistance.","Data confirm potential of BP1001-A to treat obesity in Type 2 diabetes patients.","Pre-clinical testing in HepG2 liver cell model supports earlier results in muscle cells.","Next step: mouse model study; IND filing expected in 2025 for Phase 1 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151231,"accession_number":"0001104659-25-041256","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Bio-Path issues $161K promissory note to Quick Capital; default-conversion at 65% of low bid","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $161K, purchase price $140K after $21K original issue discount.","12% one-time interest; five payments from Oct 2025 to Feb 2026 ($90,160 first, then $22,540 each).","Upon default, conversion at 65% of lowest closing bid price over 10 prior trading days; default penalty 150% plus 22% interest.","Unregistered sale under Rule 506(b) / Section 4(a)(2); use of proceeds for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170123,"accession_number":"0001558370-25-003922","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Path Holdings FY2024 net loss $9.9M; cash $1.2M; clinical progress in obesity and AML","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.9M ($4.12 per share) vs $16.1M ($33.63 per share) in FY2023.","Cash and cash equivalents of $1.2M as of Dec 31, 2024; net cash used in operations $10.6M.","R&D expense decreased to $7.3M from $11.6M; G&A expense increased to $4.7M.","Preclinical BP1001-A shows restored insulin sensitivity; Phase 1/1b BP1002 in AML progressed to 90 mg/m² dose cohort.","Patent portfolio expanded: 7 US patents, 61 foreign patents; new patents in US and NZ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170122,"accession_number":"0001104659-25-029376","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Bio-Path issues $100K promissory note with default conversion at 65% of bid price","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Net proceeds of $87,000 after $13,050 original issue discount; note principal $100,050.","12% interest; payments begin Sep 30, 2025 ($56,028), then four monthly $14,007 payments.","On default, note payable at 150% of outstanding plus 22% default interest.","Upon default, lender may convert to common at 65% of lowest closing bid over prior 10 trading days.","Company had 8,308,007 shares outstanding; conversion shares unregistered under Reg D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170121,"accession_number":"0001558370-25-003241","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Path pre-clinical data shows BP1001-A restores insulin sensitivity, supporting obesity/T2D potential","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BP1001-A attenuated palmitic acid-induced insulin resistance in C2C12 myoblasts and myotubes.","Final pre-clinical mouse model study expected H1 2025; IND filing planned by year-end.","BP1001-A downregulates Grb2 expression to increase insulin sensitivity in muscle cells.","CEO cites need for alternative glucose-lowering treatments in obese T2D patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170120,"accession_number":"0001104659-25-021789","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Bio-Path Holdings enters $161,000 promissory note financing with 1800 Diagonal Lending","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $161,000 promissory note at $140,000 after $21,000 OID; 12% one-time interest.","Five payments: $90,160 due Aug 30, 2025, then $22,540 through Dec 30, 2025.","Upon default, 22% interest and conversion at 65% of lowest 10-day closing bid price.","Proceeds for working capital; unregistered exempt under Section 4(a)(2) and Reg D.","Company had 8,308,007 common shares outstanding as of this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170119,"accession_number":"0001558370-25-001051","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq delists Bio-Path Holdings for failure to meet equity requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Bio-Path on Feb 14, 2025; trading suspended at open on Feb 19, 2025.","Company failed to regain compliance with $2.5M minimum stockholders’ equity by Jan 31, 2025.","Common stock expected to trade on OTC Markets under symbol BPTH starting Feb 19, 2025.","Company does not intend to request a review of the Panel's delisting decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170118,"accession_number":"0001558370-25-000123","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Path provides 2025 clinical update; plans IND for obesity drug, advances AML & solid tumor trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prexigebersen Phase 2 AML trial: biomarker package to identify responders; expects completion of Cohort 2 & interim analysis for Cohort 3 in 2025.","BP1001-A Phase 1/1b solid tumors advanced to second dose cohort; one patient had 15% tumor reduction after 9 cycles; second/third cohorts expected to complete 2025.","BP1002 Phase 1/1b relapsed/refractory AML: third dose cohort (60 mg/m2) enrollment closed faster than expected; no dose limiting toxicities.","New preclinical program: BP1001-A for obesity in Type 2 diabetes; expects to file IND in 2025 after completing preclinical testing.","Patent portfolio includes 7 US patents, 61 foreign patents, and multiple applications pending worldwide."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187134,"accession_number":"0001558370-24-016391","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Path reports preclinical data for BP1001-A: enhanced insulin sensitivity in obesity/T2D models","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BP1001-A reduced Grb2 protein expression in myoblast cells and increased p-AKT and p-FOXO-1 in myoblast and hepatoma cells.","Data confirm mechanism of action via insulin/PI3K/AKT pathway; supports BP1001-A as obesity/T2D treatment.","Animal studies initiated; if successful, Phase 1 clinical trial planned for 2025.","CEO cites unmet need from existing weight-loss drugs failing in obese T2D patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187133,"accession_number":"0001104659-24-128517","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["3.01","5.02","5.07","9.01"],"status":"ready","headline":"Bio-Path receives Nasdaq bid-price deficiency notice; shareholders OK reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq letter Dec 12, 2024: closing bid below $1 for 30 straight days; 180 days until June 10, 2025 to comply.","Stockholders approved reverse stock split up to 1-for-30 to potentially cure deficiency.","Approved increase in 2022 Stock Incentive Plan shares by 1,200,000 to total 1,265,000 shares.","Ratified Ernst & Young as independent auditor for fiscal year ending Dec 31, 2024.","All five director nominees elected with over 80% of votes cast for each."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187132,"accession_number":"0001558370-24-016182","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Path outlines obesity program for BP1001-A; discontinues BP1002 Phase 1 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BP1001-A aims to treat obesity in Type 2 diabetes by downregulating Grb2 to enhance insulin signaling.","IND-enabling testing for BP1001-A expected in Q4 2024; preclinical studies ongoing.","Discontinues Phase 1 study of BP1002 for lymphoma/CLL due to enrollment challenges.","Company reallocates resources to metabolic program from oncology pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187131,"accession_number":"0001104659-24-122574","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nasdaq panel grants Bio-Path continued listing subject to $2.5M equity compliance by Jan 31, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company must demonstrate minimum $2.5M stockholders' equity by Jan 31, 2025 to remain listed.","If conditions not met, Bio-Path may face delisting from Nasdaq Capital Market.","Company previously received deficiency notice in March 2024, extension in June 2024, and delisting determination in September 2024.","Bio-Path intends to pursue compliance but cautions there is no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187130,"accession_number":"0001558370-24-015779","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Path Q3 net loss $2.1M; expands DNAbilize into obesity; cash $0.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.1M ($0.70 per share) vs $3.2M ($6.36) in Q3 2023; R&D expense down to $1.3M from $2.3M.","Cash of $0.6M as of Sept 30, 2024 (Dec 31, 2023: $1.1M); operating cash burn $7.7M YTD 2024.","Initiated BP1001-A obesity program in October, first non-oncology application of DNAbilize technology targeting Grb2 insulin resistance.","Completed enrollment for third dose cohort of BP1002 Phase 1/1b trial in venetoclax-resistant AML patients ahead of schedule.","Closed $4.0M private placement in October: 4.6M shares and warrants at $0.87 per unit."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187129,"accession_number":"0001558370-24-013246","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Bio-Path raises ~$4M in private placement; launches obesity drug program BP1001-A","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.0M from private placement of pre-funded warrants and series A/B warrants at $0.87 per unit; warrants exercisable at $1.00 per share.","Initiated development of BP1001-A for obesity using DNAbilize technology; IND-enabling testing expected to begin in Q4 2024.","Completed enrollment of third dosing cohort (60 mg/m2) of Phase 1/1b trial of BP1002 in refractory/relapsed AML patients.","Cancelled prior June 2024 series A and B warrants (1,809,955 shares each) held by the same investor upon closing of this placement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203651,"accession_number":"0001558370-24-012780","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bio-Path receives Nasdaq delisting notice for equity non-compliance; plans appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq delisting letter on Sept 12, 2024 for failing to meet $2.5M stockholders' equity requirement.","Trading suspension set for Sept 23, 2024 unless appeal requested by Sept 19, 2024.","Company intends to request hearing before Nasdaq Hearings Panel to stay suspension.","No assurance that appeal will succeed; stock continues trading under BPTH pending Panel decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203650,"accession_number":"0001558370-24-012413","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Path reports solid tumor patient response to BP1001-A; AML patients show extended remission","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient at 90 mg/m2 dose of BP1001-A had 15% tumor reduction and stable disease after 6 cycles.","Patient is elderly female with gynecologic cancer, heavily pretreated with chemotherapy and surgeries.","Two elderly AML patients in Phase 2 triple combo (prexigebersen/decitabine/venetoclax) remain in complete remission: one at 16 cycles/21 months, another at 12 cycles/14 months.","Phase 1b of BP1001-A expected to begin after three monotherapy dose cohorts; will test combo with paclitaxel and gemcitabine.","Management highlights platform potential for targeted protein inhibition with favorable safety profile."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203649,"accession_number":"0001558370-24-012293","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Path posts Q2 2024 net loss of $1.9M; cash position improves to $4.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.9M ($1.16 per share) vs $4.2M ($10.64 per share) in Q2 2023.","Cash $4.0M at June 30, 2024, up from $1.1M at Dec 31, 2023; operating cash burn $4.3M.","Closed $4.0M private placement in June: 1.8M shares + warrants at $2.21/share.","R&D expense down to $1.9M from $3.1M; G&A flat at $1.2M.","Presented interim Phase 2 data for prexigebersen in AML at ASCO and EHA."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203648,"accession_number":"0001558370-24-009750","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bio-Path provides clinical update; expands prexigebersen into obesity preclinical studies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 AML trial paused for interim analysis; expects to complete enrollment in cohorts 1&2 over 18 months.","Phase 1/1b BP1001-A advanced to dose level 2; expects dose level 3 by year-end.","Phase 1/1b BP1002 completed second dose cohort (40 mg/m2); advancing to dose level 3 in Q4 2024.","Developed molecular biomarkers for prexigebersen; preparing preclinical obesity studies.","Phase 1 BP1002 in lymphoma/CLL enrolling second dose cohort; results expected year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220174,"accession_number":"0001558370-24-009211","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bio-Path gets Nasdaq extension to Sept 8 to meet $2.5M equity rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Non-compliance with Nasdaq minimum stockholders' equity of $2.5M noted March 12, 2024.","Compliance plan submitted April 26, 2024; extension granted June 12, 2024 through Sept 8, 2024.","If not compliant by Sept 8, delisting subject to appeal to Nasdaq Hearings Panel.","Company intends to pursue compliance but no assurance of success or appeal outcome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220173,"accession_number":"0001558370-24-009170","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Path interim Phase 2 data: 75% CR/CRh/CRi in newly diagnosed AML with prexigebersen combo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohort 1 (newly diagnosed): 15/20 evaluable patients achieved CR/CRh/CRi; median age 75, adverse-risk or secondary AML.","Cohort 2 (relapsed/refractory): 55% of evaluable patients (12/23) achieved CR/CRh/CRi with same triple combination.","Most common severe adverse events: febrile neutropenia (26%) and sepsis (5%); safety consistent with backbone therapy.","Company to continue enrollment up to 98 evaluable for Cohort 1 and 54 for Cohort 2.","Results presented at EHA Congress 2024; CEO highlights potential as additional AML treatment option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220172,"accession_number":"0001104659-24-068736","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Bio-Path Holdings raises $4.0M in private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.0M from sale of 1,809,955 shares (or equivalents) and warrants at $2.21 per unit.","Series A warrants (5-year term) and Series B warrants (24-month term), each exercisable at $2.00/share.","H.C. Wainwright acted as exclusive placement agent, receiving 7.5% cash fee and placement agent warrants.","Net proceeds to be used for working capital and general corporate purposes.","Securities unregistered; company agreed to file resale registration statement within 15 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220171,"accession_number":"0001558370-24-008844","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bio-Path presents positive Phase 2 prexigebersen data at ASCO; 75% CR/CRh/CRi in newly diagnosed AML","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohort 1 (newly diagnosed AML): 75% of evaluable patients (15/20) achieved CR/CRh/CRi; median age 75 yrs, adverse-risk or sAML.","Cohort 2 (relapsed/refractory AML): 55% of evaluable patients (12/23) achieved CR/CRi/CRh; median age 63 yrs.","Safety profile consistent with decitabine+venetoclax; common AEs: fatigue (72%), anemia (60%), neutropenia (49%).","Bio-Path plans to continue enrollment up to 98 evaluable in Cohort 1 and 54 evaluable in Cohort 2.","Data presented as oral presentation at ASCO 2024 by MD Anderson investigator; CEO highlights unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220170,"accession_number":"0001558370-24-008779","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Path presents positive interim Phase 2 prexigebersen AML data at ASCO and EHA","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["ASCO oral presentation on June 1, 2024 (8:00 AM CT, McCormick Place, abstract #6511).","EHA poster presentation on June 14, 2024 (6:00 PM CEST, Madrid, abstract #P536).","Interim Phase 2 data for prexigebersen (BP1001) plus decitabine/venetoclax in AML show it's well-tolerated with compelling efficacy.","Data from newly diagnosed and refractory/relapsed cohorts both exceeded outcomes with frontline therapy.","No specific numerical results were disclosed in the press releases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220169,"accession_number":"0001544784-24-000068","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Path Q1 net loss $3.2M ($4.88/sh); raises $3.5M post-quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.2M ($4.88 EPS) vs $5.3M ($13.25 EPS) in Q1 2023; R&D expense down to $2.3M from $4.0M.","Cash at Mar 31 only $0.2M; raised $3.5M in April via $1.2M direct offering and $2.3M ATM sales.","Completed second dose cohort (40 mg/m2) of Phase 1/1b BP1002 trial for relapsed AML; pause for FDA review.","Patent portfolio expanded to 5 U.S. and 54 foreign patents covering 21 countries; new applications filed.","First dose cohort of Phase 1 BP1002 trial for relapsed lymphoma/CLL completed in January."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220168,"accession_number":"0001104659-24-049400","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bio-Path raises additional $1.1M ATM capacity after completing initial $2M sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 436,511 shares for ~$2.0M gross proceeds under prior ATM; offering terminated April 19, 2024.","New ATM prospectus supplement filed to sell up to additional $1,107,871 of common stock.","Proceeds from the expanded ATM will be used for working capital and general corporate purposes.","H.C. Wainwright & Co. acts as sales agent; no minimum offering and no obligation to sell.","Shares offered under existing shelf registration statement (333-265282) declared effective June 14, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220167,"accession_number":"0001104659-24-049197","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Bio-Path Holdings raises $1.2M in registered direct offering and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 375,000 shares at $3.225 per share for gross proceeds of $1.2 million.","Concurrent private placement of warrants to purchase 375,000 shares at $3.10 per share.","Net proceeds of ~$1.0M after fees; intended for working capital and general purposes.","Offering expected to close April 19, 2024; H.C. Wainwright acted as placement agent.","Outstanding shares will increase from 1,190,306 to 1,565,306 post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220166,"accession_number":"0001558370-24-005280","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bio-Path completes second dose cohort in Phase 1/1b trial of BP1002 in AML","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second dose cohort (40 mg/m²) completed in dose escalation for refractory/relapsed AML patients, including venetoclax-resistant.","Trial will pause for FDA data review; next planned dose is 60 mg/m² in monotherapy.","BP1002 targets Bcl-2 at mRNA level, may overcome venetoclax resistance; preclinical data showed potent inhibition.","Phase 1b combination with decitabine expected after monotherapy cohorts; enrollment rates described as good."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220165,"accession_number":"0001558370-24-005060","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bio-Path expands global patent portfolio with new patents in Mexico, Australia, Japan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received newly issued patents in Mexico (IGF-1R inhibition), Australia (STAT3, IGF-1R, BCL2 inhibition), and Japan (liposomal formulation).","Portfolio now includes 5 issued US patents and 54 foreign patents covering 21 countries.","Expects six additional patent grants this year; 51 pending applications across six families.","Patents protect DNAbilize antisense platform and provide 20 years of exclusivity for new targets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220164,"accession_number":"0001104659-24-043661","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bio-Path enters ATM agreement for up to $2M common stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered At The Market Offering Agreement with H.C. Wainwright & Co. for up to $2.0M of common stock.","Sales agent commission set at 3.0% of aggregate gross proceeds from each sale.","Shares sold at market prices; Company not obligated to sell and may suspend or terminate.","Offering made under effective shelf registration (File No. 333-265282) and prospectus supplement filed April 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220163,"accession_number":"0001558370-24-004601","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Path provides 2024 clinical update: AML, solid tumor trials advancing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 prexigebersen trial in AML targets FDA Fast Track for fragile patients; median survival 5-10 months.","Phase 1/1b BP1001-A in solid tumors advanced to second dose level; Phase 1b with paclitaxel planned.","Phase 1/1b BP1002 in relapsed/refractory AML enrolling at 40 mg/m2; no DLTs at 20 mg/m2.","Phase 1 BP1002 in lymphoma/CLL enrolling second dose cohort (40 mg/m2) after no DLTs.","Patent portfolio: 5 US and 53 foreign issued patents covering DNAbilize technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239875,"accession_number":"0001558370-24-004012","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bio-Path Holdings closes $300K registered direct offering with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 75,000 shares of common stock at $3.99 per share in a registered direct offering, raising ~$299,250.","Issued warrants to purchase up to 75,000 shares (100% coverage) at an exercise price of $3.865 per share.","Offering was previously disclosed on March 25, 2024; legal opinion from Winstead PC filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239874,"accession_number":"0001104659-24-038742","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Bio-Path raises ~$299k in registered direct offering; issues warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $299,250 from 75,000 shares at $3.99/share; net ~$0.2M after fees.","Common warrants to purchase up to 75,000 shares at $3.865, 5-year term, immediate exercise.","Placement agent H.C. Wainwright gets 7.5% fee plus warrants for 5,625 shares at $4.9875.","Proceeds for working capital; closing expected March 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239873,"accession_number":"0001558370-24-003118","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bio-Path receives Nasdaq delisting notice for failing $2.5M equity minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Deficiency letter received March 12, 2024 citing non-compliance with Nasdaq Listing Rule 5550(b)(1).","Company has until April 26, 2024 to submit a plan to regain compliance.","If plan accepted, Nasdaq may grant up to 180 days extension to cure deficiency.","Common stock continues trading on Nasdaq Capital Market under symbol BPTH pending review.","Company evaluating options but no assurance of regaining compliance or avoiding delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239872,"accession_number":"0001558370-24-002853","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bio-Path regains Nasdaq minimum bid price compliance; delisting risk resolved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq letter on March 8, 2024 confirming bid price compliance.","Closing bid price at or above $1.00 for 10 consecutive days through March 7, 2024.","Nasdaq Rule 5550(a)(2) matter closed; continued listing on Nasdaq Capital Market.","No other material changes or events disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239871,"accession_number":"0001558370-24-002780","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Path Holdings FY2023 net loss $16.1M; cash drops to $1.1M from $10.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.1M ($33.63 per share) vs $13.9M ($38.12 per share) in FY2022.","Cash at Dec 31, 2023: $1.1M, down from $10.4M a year earlier.","R&D expense rose to $11.6M from $9.2M on manufacturing and trial enrollment.","Completed first dose cohort in Phase 1/1b trial of BP1002 for AML and Phase 1 trial for lymphoma/CLL.","G&A fell to $4.2M from $4.7M; net cash used in ops $11.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239870,"accession_number":"0001558370-24-001573","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-02-23T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Bio-Path Holdings announces 1-for-20 reverse stock split effective Feb 22, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-20 effective 5:30 p.m. ET Feb 22, 2024; trading starts split-adjusted on Nasdaq under BPTH on Feb 23.","Shares outstanding reduced from ~12.35M to ~617,833; no fractional shares issued.","New CUSIP number 09057N409; par value unchanged; all options/warrants adjusted.","Company uses DNAbilize antisense RNAi nanoparticle tech for cancer drugs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239869,"accession_number":"0001558370-24-000716","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bio-Path shareholders approve reverse stock split up to 1-for-50 at special meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse stock split proposal approved with 3,730,379 votes for and 3,189,586 against; 42,153 abstentions.","Ratio of up to 1-for-50, exact ratio to be determined by Board of Directors.","Special meeting was reconvened after initial adjournment to solicit additional proxies.","No broker non-votes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239868,"accession_number":"0001558370-24-000438","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-01-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bio-Path Holdings adjourns special meeting to Jan 30 for reverse split vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved adjournment (4.05M for, 2.31M against) to solicit additional proxies.","Proposal for up to 1-for-50 reverse stock split not yet voted; meeting reconvenes Jan 30, 2024.","Record date remains Dec 28, 2023; meeting location in The Woodlands, Texas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239867,"accession_number":"0001558370-24-000184","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Path completes first dose cohort in Phase 1 trial of BP1002 for lymphoma/CLL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BP1002, a liposomal Bcl-2 antisense, advanced to next dose cohort (40 mg/m²) after completing 20 mg/m² cohort safely.","Trial targets refractory/relapsed lymphoma and CLL patients, including those who failed venetoclax-based therapy.","Phase 1 uses 3+3 design; six evaluable patients per cohort; enrollment open for second cohort.","BP1002 targets Bcl-2 mRNA, potentially overcoming BH3 domain mutations causing venetoclax resistance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257393,"accession_number":"0001558370-23-019841","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bio-Path Holdings stockholders elect five director nominees, ratify Ernst & Young as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Peter H. Nielsen, Heath W. Cleaver, Paul D. Aubert, Aline Sherwood, Douglas P. Morris.","Ratification of Ernst & Young as independent auditor for FY2023 approved with 5,881,335 for and 78,314 against.","Broker non-votes on director election totaled 4,018,949 shares; no broker non-votes on auditor ratification.","Annual meeting held and votes tallied on December 14, 2023; results filed December 15, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257392,"accession_number":"0001558370-23-019795","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bio-Path completes first dose cohort of BP1002 Phase 1/1b trial in AML; no dose-limiting toxicities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First cohort (20 mg/m2) completed with no dose-limiting toxicities in 3 evaluable refractory/relapsed AML patients.","BP1002 uses RNAi to limit Bcl-2 protein production, offering potential treatment for venetoclax-resistant patients.","Treatment cycle: two doses per week for 4 weeks (8 doses over 28 days).","Phase 1b portion will assess BP1002 in combination with decitabine after monotherapy cohorts.","National PI is Dr. Gail Roboz, director of Clinical and Translational Leukemia Program at Weill Cornell."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257391,"accession_number":"0001558370-23-019691","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Bio-Path Holdings reduces stockholder meeting quorum to one-third of shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Amendment No. 1 to Bylaws on Dec 7, 2023, reducing quorum from majority to one-third of shares entitled to vote at stockholder meetings.","Amendment effective immediately upon Board adoption; no change in fiscal year.","Change is a procedural governance adjustment to facilitate convening meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257390,"accession_number":"0001558370-23-019085","cik":1133818,"company_name":"BIO-PATH HOLDINGS, INC.","ticker":"BPTH","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bio-Path Q3 net loss $3.2M; positive prexigebersen AML Phase 2 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.2M ($0.32/sh) vs $3.5M ($0.49/sh) in Q3 2022, improvement from lower expenses and warrant income.","Cash $2.4M as of Sep 30, 2023, down from $10.4M at Dec 31, 2022; net cash used in ops $9.7M in nine months.","Positive Phase 2 interim data for prexigebersen in AML; results exceed outcomes of decitabine/venetoclax alone.","R&D expense $2.3M (down from $2.4M), G&A $1.0M (down from $1.2M) year-over-year.","KOL event in October with MD Anderson and Georgia Cancer Center experts discussing prexigebersen potential."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2097404.0594594595,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-11-15T23:59:59+00:00|257390"}